ReviewExpert review of vaccines2019
Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States.
Review in Expert review of vaccines, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Effectiveness of pneumococcal vaccination in reducing hospitalization and mortality among the elderly: A systematic review and meta-analysis.Human vaccines & immunotherapeutics · 2025Pooled it
- Systematic review of the efficacy, effectiveness and impact of high-valency pneumococcal conjugate vaccines on otitis media.Human vaccines & immunotherapeutics · 2022Pooled it
- Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- Article
- Review
- Prevalence, Clinical Severity, and Serotype Distribution of Pneumococcal Pneumonia Among Adults Hospitalized With Community-Acquired Pneumonia in Tennessee and Georgia, 2018-2022.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Effects of sequential vs single pneumococcal vaccination on cardiovascular diseases among older adults: a population-based cohort study.International journal of epidemiology · 2024Article
- Article
- 20‑Valent Pneumococcal Conjugate Vaccine: Pediatric First Approval.Paediatric drugs · 2023Review
- PfaSTer: a machine learning-powered serotype caller forMicrobial genomics · 2023Article
- Burden of Hospitalizations Related to Pneumococcal Infection in Spain (2016-2020).Antibiotics (Basel, Switzerland) · 2023Article
- PCV13 Pediatric Routine Schedule Completion and Adherence Before and During the COVID-19 Pandemic in the United States.Infectious diseases and therapy · 2022Article
- Urban and Rural Disparities in Pneumococcal Carriage and Resistance in Jordanian Children, 2015-2019.Vaccines · 2021Article
- Article
- Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance.Vaccines · 2021Review
- Unraveling the Impact of Pneumococcal Conjugate Vaccines on Bacterial Conjunctivitis in Children.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Clinical Features and Outcomes of Community-Acquired Pneumonia Caused byOpen forum infectious diseases · 2021Article
- Multi-Valent Protein Hybrid Pneumococcal Vaccines: A Strategy for the Next Generation of Vaccines.Vaccines · 2021Review
- Impact of the 13-valent pneumococcal conjugate vaccine on the incidences of community-acquired pneumonia and pneumonia-related hospitalizations in children ≤5 years after its implementation into the national immunization program of Turkey.Human vaccines & immunotherapeutics · 2020Article
- To Boost or Not to Boost? Lessons from the Australian Pneumococcal Conjugate Vaccination Program.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
introductionPneumonia is one of the leading causes of morbidity and mortality among children and older adults. Pneumococcal conjugate vaccines (PCVs) were introduced into the US routine infant vaccination schedule leading to substantial reductions of invasive pneumococcal diseases (IPD). PCV introduction also led to reductions in all-cause pneumonia among US children, though the indirect impact of PCVs on pneumonia in adults is difficult to quantify, especially due to the recent US recommendation for direct PCV use in older adults. Areas covered: We described the existing evidence for both the direct and indirect impact of PCVs on pneumonia among children and adults in the US since PCV introduction. Expert commentary: The introduction of PCVs into the US routine infant vaccination schedule led to important reductions in the burden of IPD and non-invasive pneumonia among vaccinated and unvaccinated populations. The impact of direct vaccination of older adults in the US since 2014, though difficult to quantify, is currently being evaluated. As pneumonia remains one of the leading causes of morbidity and mortality in the US, future evaluations of the direct and indirect effects of current and expanded valency PCVs in the US population are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.